Cover Image
市場調查報告書

下一代癌症診斷市場規模與預測:各技術 (DNA,蛋白質微陣列,實驗室晶片,RT-PCR及多工處理,次世代定序) 各功能,癌症的各類型,各用途,及2015∼2022年趨勢分析

Next Generation Cancer Diagnostics Market Size & Forecast By Technology (DNA & Protein Microarrays, Lab-on-a-chip, RT-PCR & Multiplexing, & NGS Sequencing), By Function, By Cancer Type, By Application And Trend Analysis From 2015 To 2022

出版商 Grand View Research, Inc. 商品編碼 355251
出版日期 內容資訊 英文 75 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
下一代癌症診斷市場規模與預測:各技術 (DNA,蛋白質微陣列,實驗室晶片,RT-PCR及多工處理,次世代定序) 各功能,癌症的各類型,各用途,及2015∼2022年趨勢分析 Next Generation Cancer Diagnostics Market Size & Forecast By Technology (DNA & Protein Microarrays, Lab-on-a-chip, RT-PCR & Multiplexing, & NGS Sequencing), By Function, By Cancer Type, By Application And Trend Analysis From 2015 To 2022
出版日期: 2016年02月22日 內容資訊: 英文 75 Pages
簡介

全球下一代癌症診斷市場今後預計以32.0%的年複合成長率 擴大,至2022年達到202億5,000萬美元。由於癌症的發病率上升,一般認為對早期診斷和促進有效率的預後的下一代癌症診斷檢驗的需求高漲。再加上為了增加癌症診斷和預防性診斷為對象的研究計劃數,政府熱誠的努力,也對市場成長有貢獻。

本報告提供全球下一代癌症診斷市場現狀與至2022年的成長預測,各技術,各功能,癌症的各類型,各用途趨勢,以及主要企業的簡介等彙整。

第1章 調查方法與調查範圍

第2章 摘要整理

第3章 產業預測

  • 市場區隔
  • 市場規模與成長預測
    • 促進要素
    • 阻礙要素
  • 下一代癌症診斷市場趨勢
  • 主要的機會
  • 產業分析:波特
  • PESTEL分析

第4章 各技術市場預測

  • DNA微陣列
  • 蛋白質微陣列
  • 實驗室晶片
  • RT-PCR及多工處理
  • 次世代定序

第5章 各功能預測

  • 風險分析
  • 癌症篩檢
  • 預後診斷
  • 治療監測
  • 搭配診斷

第6章 各用途預測

  • 遺傳基因分析
  • 表觀遺傳學分析
  • CTC分析
  • 蛋白質體學分析
  • 生物標記開發

第7章 癌症的各類型預測

  • 乳癌
  • 子宮頸癌
  • 大腸癌
  • 肺癌
  • 其他

第8章 各地區預測

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第9章 競爭環境

  • Johnson & Johnson
  • Novartis AG
  • Roche Holding AG
  • Philips Electronics NV
  • Abbott Laboratories
  • GE Healthcare
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies Inc
  • Perkin Elmer Inc.
  • Illumina Inc.
  • Qiagen
  • Hologic Inc.
  • Myriad Genetics Inc.
  • Almac Group Ltd.
  • Cepheid
  • Exosome Diagnostics Inc.
  • Genomic Health Inc.
  • Opko Health Inc.
  • Sysmex

圖表

目錄
Product Code: 978-1-68038-738-4

Global next generation cancer diagnostics market is anticipated to reach USD 20.25 billion by 2022 growing at an estimated CAGR of 32.0% from 2015 to 2022, according to a new report by Grand View Research Incorporated. Rising incidence of oncology diseases is anticipated to drive the demand for next generation cancer diagnostic tests that are expected to enhance early diagnosis and efficient prognosis of various forms of cancers is a factor expected to positively influence sector growth over the forecast period.

Cancer diagnostics industry is estimated to witness lucrative growth over the forecast period majorly due to rising number of technologically advanced products in the field of companion diagnostics, providing more precise testing results combined with therapeutic monitoring early diagnosis of cancer. Moreover, there is a significant shift observed from traditional laboratory testing to rapid point of care testing, which fuels growth in the market owing to expected commercialization of technologically advanced range of products including diagnostic kits, instruments, and reagents.

Furthermore, supportive government initiatives in order to increase the number of research projects with respect to oncology and preventative diagnosis is expected to be attributive for growth in this sector overthe coming years. Additionally, application of tumor diagnostics in epigenetic analysis and CTC enumeration for monitoring tumorigenesis is expected to support projected growth over the forecast period.

Further key findings from the report suggest:

RT-PCR & multiplexing accounted for the largest share of the market in 2014 with respect to technologies because of the presence of a wide product portfolio that caters to a number of applications in oncology R&D.

Next generation sequencing solutions for use in cancer diagnostics are expected to witness lucrative growth in revenue over the forecast period owing to the considerable number of advantages the technology offers over its counterpart segment i.e. microarrays. Introduction of novel sequencing platforms and growth oriented initiatives taken by major market participants are other key factors expected to fuel segment growth.

In January 2016, Illumina launched its MiniSeq system for the sequencing, which provides complete sequencing solution in order to obtain quicker results because of onboard data analysis for numerous assays and workflow with easy-to-use library-to-results. Such strategic initiatives taken by major market entities are also expected to drive this segment further over the forecast period.

Development and expected commercialization of a number of companion diagnostics is a key factor attributive of anticipated substantial growth in demand and progress of the segment over the next seven years owing to rising sector penetration in this segment for use with therapeutics and novel pharmaceuticals as adjunct in monitoring tumor eradication.

Dominant industry participants to produce non-small cell lung cancer diagnostic tests anticipate lung cancer to witness substantial growth in market demand because of product development operations carried out.

Application of oncology diagnostics in biomarker discovery by transcription regulation is expected to drive industry with potential growth avenues as it subsequently proves helpful in drug designing and identification of novel targets for tumor eradication

North America held the largest share with respect to revenue generation in 2014 due to simultaneous development of next generation sequencing, personalized medicine and companion diagnostics in the region. Furthermore, high R&D investment as well as availability of technologically advanced healthcare research framework, is expected to serve as a critical factor for the North American region to register considerable growth over the forecast period.

Presence of significant developments by China and Japan for technological integration, and the development of healthcare infrastructure have poised the Asia Pacific oncology diagnostics market to witness lucrative opportunities of growth throughout the forecast period. Moreover, enhancements of clinical development frameworks in these economies to enable clinical research outsourcing as an effect of the availability of target population is a growth rendering driver in this region.

Key players contributing significantly to the next generation cancer diagnostics market are Novartis AG, Cepheid, Roche Holdings AG, Perkin Elmer Inc., Sysmex Corporation, Abbott Laboratories, Thermo Fisher Scientific Inc., Philips Electronics NV, Agilent Technologies Inc., Illumina Inc., Genomic Health Inc. Qiagen, Johnson & Johnson, Hologic Inc., Myriad Genetics Inc., Almac Group Limited, Opko Health Inc., and GE Healthcare,

These entities are involved in collaborations with oncology research organizations and clinical research institutes in order to gain access in the oligopolistic market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Scope & Assumptions
  • 1.3. List of Data Sources

Chapter 2. Executive Summary

Chapter 3. Next Generation Cancer Diagnostics Industry Outlook

  • 3.1. Market Segmentation
  • 3.2. Market Size and Growth Prospects
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Next Generation Cancer Diagnostics Market Dynamics
  • 3.4. Key Opportunities Prioritized, 2014
  • 3.5. Industry Analysis -Porter's
  • 3.6. Next Generation Cancer Diagnostics Market PESTEL Analysis

Chapter 4. Next Generation Cancer Diagnostics Technology Outlook

  • 4.1. DNA Microarrays
    • 4.1.1. DNA Microarrays Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 4.2. Protein Microarrays
    • 4.2.1. Protein Microarrays Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 4.3. Lab-on-a-chip
    • 4.3.1. Lab-on-a-chip Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 4.4. RT-PCR & Multiplexing
    • 4.4.1. RT-PCR & Multiplexing Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 4.5. NGS Sequencing
    • 4.5.1. NGS Sequencing Market Estimates and Forecasts, 2015 - 2022 (USD Million)

Chapter 5. Next Generation Cancer Diagnostics Outlook, By Function

  • 5.1. Risk Analysis
    • 5.1.1. Risk Analysis Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 5.2. Cancer Screening
    • 5.2.1. Cancer Screening Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 5.3. Prognosis Diagnostics
    • 5.3.1. Prognosis Diagnostics Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 5.4. Therapeutic Monitoring
    • 5.4.1. Therapeutic Monitoring Market Estimates and Forecasts, 2015 - 2022 (USD Million
  • 5.5. Companion Diagnostics
    • 5.5.1. Companion Diagnostics Market Estimates and Forecasts, 2015 - 2022 (USD Million)

Chapter 6. Next Generation Cancer Diagnostics Application Outlook

  • 6.1. Genetic Analysis
    • 6.1.1. Genetic Analysis Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 6.2. Epigenetic Analysis
    • 6.2.1. Epigenetic Analysis Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 6.3. CTC Analysis
    • 6.3.1. CTC Analysis Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 6.4. Proteomic Analysis
    • 6.4.1. Proteomic Analysis Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 6.5. Biomarker Development
    • 6.5.1. Biomarker Development Market Estimates and Forecasts, 2015 - 2022 (USD Million)

Chapter 7. Next Generation Cancer Diagnostics Outlook, By Cancer Type

  • 7.1. Breast Cancer
    • 7.1.1. Breast Cancer Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 7.2. Cervical Cancer
    • 7.2.1. Cervical Cancer Market Estimates and Forecasts, 2015 - 2022 (USD Million)
  • 7.3. Colorectal Cancer
    • 7.3.1. Colorectal Cancer Market Estimates and Forecasts, 2015 - 2022(USD Million)
  • 7.4. Lung Cancer
    • 7.4.1. Lung Cancer Market Estimates and Forecasts, 2015 - 2022(USD Million)
  • 7.5. Others
    • 7.5.1. Others Market Estimates and Forecasts, 2015 - 2022 (USD Million)

Chapter 8. Next Generation Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2015 - 2022)

  • 8.1. North America
    • 8.1.1. U.S.
      • 8.1.1.1. Market, by technology, 2015 - 2022 (USD Million)
      • 8.1.1.2. Market, by function, 2015 - 2022 (USD Million)
      • 8.1.1.3. Market, by cancer type, 2015 - 2022 (USD Million)
      • 8.1.1.4. Market, by application, 2015 - 2022 (USD Million)
    • 8.1.2. Canada
      • 8.1.2.1. Market, by technology, 2015 - 2022 (USD Million)
      • 8.1.2.2. Market, by function, 2015 - 2022 (USD Million)
      • 8.1.2.3. Market, by cancer Type, 2015 - 2022 (USD Million)
      • 8.1.2.4. Market, by application, 2015 - 2022 (USD Million)
  • 8.2. Europe
    • 8.2.1. Germany
      • 8.2.1.1. Market, by technology, 2015 - 2022 (USD Million)
      • 8.2.1.2. Market, by function, 2015 - 2022 (USD Million)
      • 8.2.1.3. Market, by cancer type, 2015 - 2022 (USD Million)
      • 8.2.1.4. Market, by application, 2015 - 2022 (USD Million)
    • 8.2.2. UK
      • 8.2.2.1. Market, by technology, 2015 - 2022 (USD Million)
      • 8.2.2.2. Market, by function, 2015 - 2022 (USD Million)
      • 8.2.2.3. Market, by cancer type, 2015 - 2022 (USD Million)
      • 8.2.2.4. Market, by application, 2015 - 2022 (USD Million)
    • 8.2.3. France
      • 8.2.3.1. Market, by technology, 2015 - 2022 (USD Million)
      • 8.2.3.2. Market, by function, 2015 - 2022 (USD Million)
      • 8.2.3.3. Market, by cancer type, 2015 - 2022 (USD Million)
      • 8.2.3.4. Market, by application, 2015 - 2022 (USD Million)
  • 8.3. Asia Pacific
    • 8.3.1. China
      • 8.3.1.1. Market, by technology, 2015 - 2022 (USD Million)
      • 8.3.1.2. Market, by function, 2015 - 2022 (USD Million)
      • 8.3.1.3. Market, by cancer type, 2015 - 2022 (USD Million)
      • 8.3.1.4. Market, by application, 2015 - 2022 (USD Million)
    • 8.3.2. Japan
      • 8.3.2.1. Market, by technology, 2015 - 2022 (USD Million)
      • 8.3.2.2. Market, by function, 2015 - 2022 (USD Million)
      • 8.3.2.3. Market, by cancer type, 2015 - 2022 (USD Million)
      • 8.3.2.4. Market, by application, 2015 - 2022 (USD Million)
  • 8.4. Latin America
    • 8.4.1. Brazil
      • 8.4.1.1. Market, by technology, 2015 - 2022 (USD Million)
      • 8.4.1.2. Market, by function, 2015 - 2022 (USD Million)
      • 8.4.1.3. Market, by cancer type, 2015 - 2022 (USD Million)
      • 8.4.1.4. Market, by application, 2015 - 2022 (USD Million)
  • 8.5. MEA
    • 8.5.1. South Africa
      • 8.5.1.1. Market, by technology, 2015 - 2022 (USD Million)
      • 8.5.1.2. Market, by function, 2015 - 2022 (USD Million)
      • 8.5.1.3. Market, by cancer type, 2015 - 2022 (USD Million)
      • 8.5.1.4. Market, by application, 2015 - 2022 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Johnson & Johnson
    • 9.1.1. Company Overview
    • 9.1.2. Revenue Analysis
    • 9.1.3. Product Benchmarking
    • 9.1.4. Strategic Development
  • 9.2. Novartis AG
    • 9.2.1. Company Overview
    • 9.2.2. Revenue Analysis
    • 9.2.3. Product Benchmarking
    • 9.2.4. Strategic Development
  • 9.3. Roche Holding AG
    • 9.3.1. Company Overview
    • 9.3.2. Revenue Analysis
    • 9.3.3. Product Benchmarking
    • 9.3.4. Strategic Development
  • 9.4. Philips Electronics NV
    • 9.4.1. Company Overview
    • 9.4.2. Revenue Analysis
    • 9.4.3. Product Benchmarking
    • 9.4.4. Strategic Development
  • 9.5. Abbott Laboratories
    • 9.5.1. Company Overview
    • 9.5.2. Revenue Analysis
    • 9.5.3. Product Benchmarking
    • 9.5.4. Strategic Development
  • 9.6. GE Healthcare
    • 9.6.1. Company Overview
    • 9.6.2. Revenue Analysis
    • 9.6.3. Product Benchmarking
    • 9.6.4. Strategic Development
  • 9.7. Thermo Fisher Scientific Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Revenue Analysis
    • 9.7.3. Product Benchmarking
    • 9.7.4. Strategic Development
  • 9.8. Agilent Technologies Inc
    • 9.8.1. Company Overview
    • 9.8.2. Revenue Analysis
    • 9.8.3. Product Benchmarking
    • 9.8.4. Strategic Development
  • 9.9. Perkin Elmer Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Revenue Analysis
    • 9.9.3. Product Benchmarking
    • 9.9.4. Strategic Development
  • 9.10. Illumina Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Revenue Analysis
    • 9.10.3. Product Benchmarking
    • 9.10.4. Strategic Development
  • 9.11. Qiagen
    • 9.11.1. Company Overview
    • 9.11.2. Revenue Analysis
    • 9.11.3. Product Benchmarking
    • 9.11.4. Strategic Development
  • 9.12. Hologic Inc.
    • 9.12.1. Company Overview
    • 9.12.2. Revenue Analysis
    • 9.12.3. Product Benchmarking
    • 9.12.4. Strategic Development
  • 9.13. Myriad Genetics Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Revenue Analysis
    • 9.13.3. Product Benchmarking
    • 9.13.4. Strategic Development
  • 9.14. Almac Group Ltd.
    • 9.14.1. Company Overview
    • 9.14.2. Revenue Analysis
    • 9.14.3. Product Benchmarking
    • 9.14.4. Strategic Development
  • 9.15. Cepheid
    • 9.15.1. Company Overview
    • 9.15.2. Revenue Analysis
    • 9.15.3. Product Benchmarking
    • 9.15.4. Strategic Development
  • 9.16. Exosome Diagnostics Inc.
    • 9.16.1. Company Overview
    • 9.16.2. Revenue Analysis
    • 9.16.3. Product Benchmarking
    • 9.16.4. Strategic Development
  • 9.17. Genomic Health Inc.
    • 9.17.1. Company Overview
    • 9.17.2. Revenue Analysis
    • 9.17.3. Product Benchmarking
    • 9.17.4. Strategic Development
  • 9.18. Opko Health Inc.
    • 9.18.1. Company Overview
    • 9.18.2. Revenue Analysis
    • 9.18.3. Product Benchmarking
    • 9.18.4. Strategic Development
  • 9.19. Sysmex
    • 9.19.1. Company Overview
    • 9.19.2. Revenue Analysis
    • 9.19.3. Product Benchmarking
    • 9.19.4. Strategic Development

List of Tables

  • 1. Next generation cancer diagnostics market - Industry Snapshot & Key Buying Criteria, 2015 - 2022
  • 2. Global next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 3. Global next generation cancer diagnostics market, by function 2015 - 2022 (USD Million)
  • 4. Global next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 5. Global next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 6. Global next generation cancer diagnostics market, by region, 2015 - 2022 (USD Million)
  • 7. Next generation cancer diagnostics- Key market driver analysis
  • 8. Next generation cancer diagnostics- Key market restraint analysis
  • 9. North America next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 10. North America next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 11. North America next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 12. North America next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 13. U.S. next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 14. U.S. next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 15. U.S. next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 16. U.S. next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 17. Canada next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 18. Canada next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 19. Canada next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 20. Canada next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 21. Europe next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 22. Europe next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 23. Europe next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 24. Europe next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 25. Germany next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 26. Germany next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 27. Germany next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 28. Germany next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 29. UK next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 30. UK next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 31. UK next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 32. UK next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 33. France next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 34. France next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 35. France next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 36. France next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 37. Asia Pacific next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 38. Asia Pacific next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 39. Asia Pacific next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 40. Asia Pacific next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 41. China next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 42. China next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 43. China next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 44. China next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 45. Japan next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 46. Japan next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 47. Japan next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 48. Japan next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 49. Latin America next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 50. Latin America next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 51. Latin America next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 52. Latin America next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 53. Brazil next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 54. Brazil next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 55. Brazil next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 56. Brazil next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 57. MEA next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 58. MEA next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 59. MEA next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 60. MEA next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)
  • 61. South Africa next generation cancer diagnostics market, by technology, 2015 - 2022 (USD Million)
  • 62. South Africa next generation cancer diagnostics market, by function, 2015 - 2022 (USD Million)
  • 63. South Africa next generation cancer diagnostics market, by cancer type, 2015 - 2022 (USD Million)
  • 64. South Africa next generation cancer diagnostics market, by application, 2015 - 2022 (USD Million)

List of Figures

  • 1. Next generation cancer diagnostics market segmentation
  • 2. Global next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 3. Next generation cancer diagnostics market dynamics
  • 4. Key opportunities prioritized, 2014
  • 5. Next generation cancer diagnostics market - Porter's Analysis
  • 6. Next generation cancer diagnostics market - PESTEL analysis
  • 7. Next generation cancer diagnostics revenue share, by technology, 2014 & 2022
  • 8. DNA microarray market , 2015 - 2022 (USD Million)
  • 9. Protein microarray market , 2015 - 2022 (USD Million)
  • 10. Lab-on-a-chips market , 2015 - 2022 (USD Million)
  • 11. RT-PCR & multiplexing market , 2015 - 2022 (USD Million)
  • 12. NGS sequencing market , 2015 - 2022 (USD Million)
  • 13. Next generation cancer diagnostics revenue share, by function, 2014 & 2022
  • 14. Risk analysis market , 2015 - 2022 (USD Million)
  • 15. Cancer screening market , 2015 - 2022 (USD Million)
  • 16. Prognosis diagnostics market , 2015 - 2022 (USD Million)
  • 17. Therapeutic monitoring market , 2015 - 2022 (USD Million)
  • 18. Companion diagnostics market , 2015 - 2022 (USD Million)
  • 19. Next generation cancer diagnostics revenue share, by cancer type, 2014 & 2022
  • 20. Breast cancer market , 2015 - 2022 (USD Million)
  • 21. Cervical cancer market , 2015 - 2022 (USD Million)
  • 22. Colorectal cancer market , 2015 - 2022 (USD Million)
  • 23. Unknown primary cancer market , 2015 - 2022 (USD Million)
  • 24. Leukemia market , 2015 - 2022 (USD Million)
  • 25. Lung cancer market , 2015 - 2022 (USD Million)
  • 26. Prostate cancer market , 2015 - 2022 (USD Million)
  • 27. Other cancer market , 2015 - 2022 (USD Million)
  • 28. Next generation cancer diagnostics revenue share, by application, 2014 & 2022
  • 29. Genetic analysis market , 2015 - 2022 (USD Million)
  • 30. Epigenetic analysis market , 2015 - 2022 (USD Million)
  • 31. CTC analysis market , 2015 - 2022 (USD Million)
  • 32. Proteomic analysis market , 2015 - 2022 (USD Million)
  • 33. Biomarker development market , 2015 - 2022 (USD Million)
  • 34. Next generation cancer diagnostics revenue share, by region, 2014 & 2022
  • 35. North America next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 36. U.S. next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 37. Canada next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 38. Europe next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 39. Germany next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 40. UK next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 41. France next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 42. Asia Pacific next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 43. China next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 44. Japan next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 45. Latin America next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 46. Brazil next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 47. MEA next generation cancer diagnostics market, 2015 - 2022 (USD Million)
  • 48. South Africa next generation cancer diagnostics market, 2015 - 2022 (USD Million)
Back to Top